Showing 4441-4450 of 8606 results for "".
- Robert Moccia Takes the Helm at STRATA Skin Scienceshttps://practicaldermatology.com/news/robert-moccia-takes-the-helm-at-strata-skin-sciences/2460705/Robert (Bob) Moccia is the new President and Chief Executive Officer and a member of the board of STRATA Skin Sciences, Inc. He replaces Dolev Rafaeli, PhD, who stepped down last month. “I am confident that STRATA has the technology
- Project IMPACT from VisualDX Aims to Reduce Disparities in Medicinehttps://practicaldermatology.com/news/project-impact-from-visualdx-aims-reduce-disparities-in-medicine/2460704/VisualDX is launching Project IMPACT (Improving Medicine’s Power to Address Care and Treatment), a global effort to reduce disparities in medicine and highlight ways to bridge gaps of knowledge and improve healthcare outcomes for patients of color. Inaugural members include thought leaders
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident
- With sNDA, Amgen Seeks Approval for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/with-snda-amgen-seeks-approval-for-otezla-in-mild-to-moderate-pso/2460700/Amgen has submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The sNDA is based on data from the Phase 3 ADVANCE trial tha
- Researchers Identify Mechanisms That Are Essential for Proper Skin Developmenthttps://practicaldermatology.com/news/researchers-identify-mechanisms-that-are-essential-for-proper-skin-development/2460696/Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development. This discovery could improve develop
- Registration Open for Biologic & Small Molecule NP/PA CME Virtual Bootcamphttps://practicaldermatology.com/news/registration-open-for-biologic-small-molecule-nppa-cme-virtual-bootcamp/2460689/The Biologic & Small Molecule NP/PA CME Virtual Bootcamp is coming Saturday, March 6. Topics for the program, presented by the Dermatology Education Foundation, include therapeutic updates in atopic dermatitis and psoriasis, patient initiation for biologics and small molec
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in t
- Bristol Myers Squibb: Positive Topline Results Pivotal Phase 3 Psoriasis Study of Deucravacitinibhttps://practicaldermatology.com/news/bristol-myers-squibb-positive-topline-results-pivotal-phase-3-psoriasis-study-of-deucravacitinib/2460678/Bristol Myers Squibb shared positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to s
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- People with Severe Atopic Dermatitis May Have Increased Risk of Death from Several Causeshttps://practicaldermatology.com/news/people-with-severe-atopic-dermatitis-may-have-increased-risk-of-death-from-several-causes/2460673/Although there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Im